NCT00002453已完成不适用
An Open-Label, Multicenter, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 1
研究概览
简要总结
This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.
详细描述
HIV-1-infected patients who are currently receiving stable antiretroviral therapy add tenofovir DF to their regimen. Study participation lasts for approximately 48 weeks. Interested patients should contact their physicians.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You may be eligible for this study if you:
- •Are HIV-positive.
- •Have a viral load greater than or equal to 10,000 copies/ml.
- •Have a CD4 count less than or equal to 50 cells/mm3, or have a CD4 count greater than 50 and no more than 200 cells/mm3 with an opportunistic (AIDS-related) infection within 90 days of study entry. (Patients with a CD4 count above 200 cells/mm3 may be considered depending on drug supply.)
- •Are at least 18 years old.
- •Agree to use barrier methods of birth control (such as condoms) while on the study and for 30 days afterward.
- •Have a life expectancy of at least one year.
排除标准
- •You will not be eligible for this study if you:
- •Have a history of a serious kidney or bone disease.
- •Have severe nausea, vomiting, or trouble taking medications by mouth.
- •Are pregnant or breast-feeding.
- •Abuse alcohol or other substances that your doctor thinks would interfere with taking this medicine.
- •Are taking any medicines that interfere with kidney functions.
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug CombinationsHIV InfectionsNCT00011089Gilead Sciences
已完成
3 期
Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected ChildrenHIV InfectionsNCT00528957Gilead Sciences97
Unknown
2 期
Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected ChildrenHIV InfectionsNCT00002219Gilead Sciences36
Unknown
4 期
TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal ImpairmentTenofovirRenal InsufficiencyNCT04391608Mahidol University80
已完成
不适用
Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug CombinationsHIV InfectionsNCT00002398Gilead Sciences